Slide 1: Devyser Earnings call Q1 2024
Devyser Earnings call Q1 2024 May 8, 2024
Slide 2: Today's presenters
Today’s presenters Fredrik Alpsten Sabina Berlin Theis Kipling CEO CFO CCO
Slide 3: The value of correct and fast diagnosis
The value of correct and fast diagnosis Waiting for test results is a stressful experience for patients and their families The outcome can be life-changing
Slide 4: Our mission, Our vision
Our mission Be the pioneering leader of diagnostic solutions and provide fast, accurate, and easy-to-use solutions to labs worldwide. Our vision A world where personalized medicine is universally available thanks to simplified and reliable genetic tests.
Slide 5: Our diagnostic areas
Our diagnostic areas HEREDITARY DISEASES Post- Oncology Hematology Reproductive Cystic Cardiovascular transplantation Fibrosis Diseases Health
Slide 6: Simplified workflow – faster, better and safer
Simplified workflow – faster, better and safer Traditional solutions Devyser solution Multi-step and multi-tube process Single-tube process Library STEP 1 STEP 2 purification • Faster <45 minutes hands-on time • Better Achieve turnaround time of 2-3 days • Safer Easy to use, minimize risk of sample
Slide 7: Market presence in +65 countries
Market presence in +65 countries 88%* (94%) EMEA Four sales channels - Direct sales - Partners (reported as distributor sales) - CLIA-lab (reported as 3%* (3%) direct sales) 9%* (3%) APAC - Distributor sales North & South America Distributor sales 25%* (20%) Direct sales 75%* (80%) *) LTM (Last twel
Slide 8: High sales growth
High sales growth MSEK 180,5 169,3 126,6 93,5 64,3 65,7 48,1 35,4 COVID-19 effect on 26,2 sales 14,4 2015 2016 2017 2018 2019 2020 2021 2022 2023 LTM Q1 2024 8
Slide 9: First quarter 2024
First quarter 2024
Slide 10: First quarter
First quarter ▪ Continued strong sales growth • Sales 50.7 MSEK (39.5 MSEK) • Growth + 28.5% (all organic) • Growth local currency +27.7% 10
Slide 11: First quarter
First quarter ▪ Continued strong sales growth • Sales 50.7 MSEK (39.5 MSEK) • Growth + 28.5% (all organic) • Growth local currency +27.7% ▪ Gross margin 82.7 % (85.2 %) 11
Slide 12: First quarter
First quarter ▪ Continued strong sales growth • Sales 50.7 MSEK (39.5 MSEK) • Growth + 28.5% (all organic) • Growth local currency +27.7% ▪ Gross margin 82.7 % (85.2 %) ▪ Improved EBIT • -12.2 MSEK (-19.1) 12
Slide 13: First quarter
First quarter ▪ Continued strong sales growth • Sales 50.7 MSEK (39.5 MSEK) • Growth + 28.5% (all organic) • Growth local currency +27.7% ▪ Gross margin 82.7 % (85.2 %) ▪ Improved EBIT • -12.2 MSEK (-19.1) ▪ Strong financial position • 215 MSEK in liquidity • No debts 13
Slide 14: Quarterly sales and gross margins
Quarterly sales and gross margins 14
Slide 15: Commercial outlook
Commercial outlook
Slide 16: We have four main channels
We have four main channels, and we use the channel that best serves our objective Direct sales Partners Lab services Distributors • We use Direct sales for established • Partners take a larger • Laboratory services utilizing our • We have approx. 50 distributors countries, i.e. we convert from respo
Slide 17: Agreement with Thermo Fisher Scientific
Agreement with Thermo Fisher Scientific ▪ The collaboration continues well and we remain being very optimistic for 2024 and beyond ▪ We are gearing up for the launch of additional 3 indications (Liver, Lung, Heart) for solid organs (Accept cfDNA) ▪ We are in dialogue with One Lambda around two addit
Slide 18: Devyser Genomic Laboratories
Devyser Genomic Laboratories ▪ We signed our first agreement with the UK based oncology company, Cyted incl. estimated revenues of 25 MSEK over 2 years ▪ This collaboration came nicely off the ground during Q1 and is off to a promising start ▪ Currently, RHD and Chimerism has been validated with Acc
Slide 19: Devyser CFTR NGS
• In 2023, The American College of Medical Genetics and Genomics updated its recommendations regarding the number of screening variants, from 23 to 100 Devyser • Devyser CFTR NGS one of few products that meet the new recommendations CFTR NGS • Breakthrough in the US announced on March 11 • First won
Slide 20: New FDA rule to regulate laboratory developed tests in the US
New FDA rule to regulate laboratory developed tests in the US
Slide 21: Clinical claim-based strategy in Europe and US
Devyser will pursue a clinical claim-based strategy in both Europe & US and actively working towards regulatory approvals Securing regulatory approval(s) based on solid clinical data will establish Devyser’s clinical claims and reimbursement levels as a clear competitive advantage and company edge.
Slide 22: Developing FDA & IVDR approved tests in collaboration with Illumina
Developing FDA & IVDR approved tests in collaboration with Illumina • The agreement enables Devyser to develop and commercialize IVD end-to-end solutions on the Illumina MiSeqDx NGS instrument across United States and Europe • We expect both our transplantation products as well as our product target
Slide 23: Strong development
Strong development • Really strong (and fast) development • +30 employees within R&D (assay, software, innovation, clinical affairs) • 7-8 new products launched in the last 12 months • Continued work to upgrade products from IVD to IVDR • Launching 5-10 new products within the next 6-18 months • Inv
Slide 24: Going forward
Going forward - Focus on North America and Europe - Increased US presence with the CLIA lab and our US commercial partner - Optimistic about sales development - New products in the pipeline - Continue our way to profitability 24
Slide 25: Q&A
O&A Dvysr.
Slide 26: Connect with us
Connect with us www.devyser.com